Management of chronic neuropathic pain: A protocol for a multiple treatment comparison meta-analysis of randomised controlled trials

BMJ Open

Volumn 4, Issue 11, 2014, Pages

  Mulla, Sohail M ^a,b   Buckley, D Norman ^a,c   Moulin, Dwight E ^d   Couban, Rachel ^c   Izhar, Zain ^a   Agarwal, Arnav ^a   Panju, Akbar ^a,c   Wang, Li ^a   Kallyth, Sun Makosso ^c   Turan, Alparslan ^b   Montori, Victor M ^e   Sessler, Daniel I ^b   Thabane, Lehana ^a   Guyatt, Gordon H ^a   Busse, Jason W ^a,c  

^a MCMASTER UNIVERSITY   (Canada)

^b LERNER RESEARCH INSTITUTE   (United States)

^c MCMASTER UNIVERSITY   (Canada)

^d UNIVERSITY OF WESTERN ONTARIO   (Canada)

^e MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE OUTCOME; ARTICLE; BAYES THEOREM; CHRONIC PAIN; CONCEPTUAL FRAMEWORK; DERSIMONIAN LAIRD METHOD; EVIDENCE BASED PRACTICE; HUMAN; META ANALYSIS; METHODOLOGY; MONTE CARLO METHOD; NEUROPATHIC PAIN; NUMBERS NEEDED TO TREAT; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; PROBABILITY; PUBLISHING; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY ANALYSIS; SYSTEMATIC REVIEW; ANALGESIA; COMPARATIVE STUDY; NEURALGIA;

CHRONIC PAIN; HUMANS; NEURALGIA; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 84912026385     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2014-006112     Document Type: Article

References (96)

1. Treede RD, Jensen TS, Campbell J, et al. Neuropathic pain Redefinition and a grading system for clinical and research purposes. Neurology 2008;70:1630-5.
2. Baron R, Förster M, Binder A. Subgrouping of patients with neuropathic pain according to pain-related sensory abnormalities: a first step to a stratified treatment approach. Lancet Neurol 2012;11:999-1005.
3. Meyer H. Neuropathic pain-Current concepts. S Afr Fam Practice 2008;50:40-9.
4. Gilron I, Watson CPN, Cahill CM, et al. Neuropathic pain: a practical guide for the clinician. CMAJ 2006;175:265-75.
5. O'Donnell MJ, Diener HC, Sacco RL, et al. Chronic pain syndromes after ischemic stroke: PRoFESS trial. Stroke 2013;44:1238-43.
6. Attal N. Neuropathic pain: mechanisms, therapeutic approach, and interpretation of clinical trials. Continuum (Minneapolis, Minn) 2012;18:161-75.
7. van Hecke O, Austin SK, Khan RA, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain 2014;155:654-62.
8. Doth AH, Hansson PT, Jensen MP, et al. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain 2010;149:338-44.
9. McDermott AM, Toelle TR, Rowbotham DJ, et al. The burden of neuropathic pain: results from a cross-sectional survey. Eur J Pain 2006;10:127-35.
10. Attal N, Lanteri-Minet M, Laurent B, et al. The specific disease burden of neuropathic pain: results of a French nationwide survey. Pain 2011;152:2836-43.
11. Langley PC, Van Litsenburg C, Cappelleri JC, et al. The burden associated with neuropathic pain in Western Europe. J Med Econ 2013;16:85-95.
12. Tarride J, Collet J, Choiniere M, et al. The economic burden of neuropathic pain in Canada. J Med Econ 2006;9:55-68.
13. Berger A, Dukes EM, Oster G. Clinical characteristics and economic costs of patients with painful neuropathic disorders. J Pain 2004;5:143-9.
14. Simpson EL, Duenas A, Holmes MW, et al. Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin: systematic review and economic evaluation. Health Technol Assess 2009;13:iii, ix-x, 1-154.
15. Liu H, Li H, Xu M, et al. A systematic review on acupuncture for trigeminal neuralgia. Altern Ther Health Med 2010;16:30-5.
16. Pittler MH, Ernst E. Complementary therapies for neuropathic and neuralgic pain: systematic review. Clin J Pain 2008;24:731-3.
17. Wetering EJ, Lemmens KM, Nieboer AP, et al. Cognitive and behavioral interventions for the management of chronic neuropathic pain in adults-a systematic review. Eur J Pain 2010;14:670-81.
18. Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev 2007:CD005454.
19. Goodyear-Smith F, Halliwell J. Anticonvulsants for neuropathic pain: gaps in the evidence. Clin J Pain 2009;25:528-36.
20. Eisenberg E, McNicol E, Carr DB. Opioids for neuropathic pain. Cochrane Database Syst Rev 2006;(3):CD006146.
21. Sauzet O, Williams JE, Ross J, et al. The characteristics and quality of randomized controlled trials in neuropathic pain: a descriptive study based on a systematic review. Clin J Pain 2013;29:591-9.
22. Hearn L, Derry S, Moore RA. Lacosamide for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;2: CD009318.
23. Derry S, Moore RA. Topical capsaicin (low concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2012;9: CD010111.
24. Gill D, Derry S, Wiffen PJ, et al. Valproic acid and sodium valproate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011;(10):CD009183.
25. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2011;(3):CD007938.
26. Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for acute and chronic pain in adults. Cochrane Database Syst Rev 2011;(1): CD005451.
27. Chen N, Yang M, He L, et al. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev 2010;(12): CD005582.
28. Collins S, Sigtermans MJ, Dahan A, et al. NMDA receptor antagonists for the treatment of neuropathic pain. Pain Med 2010;11:1726-42.
29. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy or chronic pain. Cochrane Database Syst Rev 2009;(4): CD007115.
30. Leung A, Donohue M, Xu R, et al. rTMS for suppressing neuropathic pain: a meta-analysis. J Pain 2009;10:1205-16.
31. Khaliq W, Alam S, Puri N. Topical lidocaine for the treatment of postherpetic neuralgia. Cochrane Database Syst Rev 2007;(2): CD004846.
32. Vargas-Espinosa ML, Sanmarti-Garcia G, Vazquez-Delgado E, et al. Antiepileptic drugs for the treatment of neuropathic pain: a systematic review. Med Oral Patol Oral Cir Bucal 2012;17:e786-93.
33. Tremont-Lukats IW, Challapalli V, McNicol ED, et al. Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis. Anesth Analg 2005;101:1738-49.
34. Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev 2012;7:CD008943.
35. Derry S, Sven-Rice A, Cole P, et al. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2013;2:CD007393.
36. Gaskell H, Moore RA, Derry S, et al. Oxycodone for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;6:CD010692.
37. Hearn L, Derry S, Phillips T, et al. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;5:CD010769.
38. Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2012;12:CD008242.
39. Moore RA, Wiffen PJ, Derry S, et al. Gabapentin for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4:CD007938.
40. Straube S, Derry S, Moore RA, et al. Cervico-thoracic or lumbar sympathectomy for neuropathic pain and complex regional pain syndrome. Cochrane Database Syst Rev 2013;9:CD002918.
41. Wiffen PJ, Derry S, Lunn MP, et al. Topiramate for neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013;8: CD008314.
42. Wiffen PJ, Derry S, Moore RA. Lamotrigine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2013;12:CD006044.
43. Wiffen PJ, Derry S, Moore RA, et al. Antiepileptic drugs for neuropathic pain and fibromyalgia-an overview of Cochrane reviews. Cochrane Database Syst Rev 2013;11:CD010567.
44. Wiffen PJ, Derry S, Moore RA, et al. Carbamazepine for chronic neuropathic pain and fibromyalgia in adults. Cochrane Database Syst Rev 2014;4:CD005451.
45. Wiffen PJ, Derry S, Moore RA, et al. Levetiracetam for neuropathic pain in adults. Cochrane Database Syst Rev 2014;7:CD010943.
46. Derry S, Wiffen PJ, Moore RA, et al. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev 2014;7: CD010958.
47. Edelsberg JS, Lord C, Oster G. Systematic review and meta-analysis of efficacy, safety, and tolerability data from randomized controlled trials of drugs used to treat postherpetic neuralgia. Ann Pharmacother 2011;45:1483-90.
48. Zakrzewska JM, Akram H. Neurosurgical interventions for the treatment of classical trigeminal neuralgia. Cochrane Database Syst Rev 2011;(9):CD007312.
49. Yang M, Zhou M, He L, et al. Non-antiepileptic drugs for trigeminal neuralgia. Cochrane Database Syst Rev 2011;(1):CD004029.
50. van Alfen N, van Engelen BG, Hughes RA. Treatment for idiopathic and hereditary neuralgic amyotrophy (brachial neuritis). Cochrane Database Syst Rev 2009;(3):CD006976.
51. Griebeler ML, Tsapas A, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis (Protocol). Syst rev 2012;1:61.
52. Wong MC, Chung JW, Wong TK. Effects of treatments for symptoms of painful diabetic neuropathy: systematic review. BMJ 2007;335:87.
53. Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2013;14:167-84.
54. Xia L, Zhong J, Zhu J, et al. Effectiveness and safety of microvascular decompression surgery for treatment of trigeminal neuralgia: a systematic review. J Craniofac Surg 2014;25:1413-17.
55. Rudroju N, Bansal D, Talakokkula ST, et al. Comparative efficacy and safety of six antidepressants and anticonvulsants in painful diabetic neuropathy: a network meta-analysis. Pain Physician 2013;16:E705-14.
56. Ney JP, Devine EB, Watanabe JH, et al. Comparative efficacy of oral pharmaceuticals for the treatment of chronic peripheral neuropathic pain: meta-analysis and indirect treatment comparisons. Pain Med 2013;14:706-19.
57. Selph S, Carson S, Fu R, et al. Drug class review: neuropathic pain: final update 1 report. Portland, OR: Oregon Health & Science University, 2011.
58. Berger VW. Is the Jadad score the proper evaluation of trials? J Rheumatol 2006;33:1710-1; author reply 1711-1712.
59. Systematic Review of Quality Assessment Instruments for Randomized Control Trials: Selection of SIGN50 Methodological Checklist. http://www.imbi.uni-freiburg.de/OJS/cca/index.php/cca/article/view/5053
60. Busse JW, Bruno P, Malik K, et al. An efficient strategy allowed English-speaking reviewers to identify foreign-language articles eligible for a systematic review. J Clin Epidemiol 2014;67:547-53.
61. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159-74.
62. Turk DC, Dworkin RH, Allen RR, et al. Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain 2003;106:337-45.
63. Turk DC, Dworkin RH, Revicki D, et al. Identifying important outcome domains for chronic pain clinical trials: an IMMPACT survey of people with pain. Pain 2008;137:276-85.
64. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA 2001;285:437-43.
65. Akl EA, Sun X, Busse JW, et al. Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol 2012;65:262-7.
66. Higgins JP, Green S. Cochrane Handbook for Systematic Reviews of Interventions, Version [5.1.0] (updated March 2011). The Cochrane Collaboration, 2011.
67. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
68. Cornell JE, Mulrow CD, Localio R, et al. Random-effects meta-analysis of inconsistent effects: a time for change. Ann Intern Med 2014;160:267-70.
69. Brockwell SE, Gordon IR. A comparison of statistical methods for meta-analysis. Stat med 2001;20:825-40.
70. Guolo A. Higher-order likelihood inference in meta-analysis and meta-regression. Stat med 2012;31:313-27.
71. Thorlund K, Walter SD, Johnston BC, et al. Pooling health-related quality of life outcomes in meta-analysis-a tutorial and review of methods for enhancing interpretability. Res Synth Methods 2011;2:188-203.
72. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002;21:1539-58.
73. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
74. Altman DG, Bland JM. Interaction revisited: the difference between two estimates. BMJ 2003;326:219.
75. Atkins D, Best D, Briss PA, et al. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.
76. Balshem H, Helfand M, Schunemann HJ, et al. RADE guidelines: 3 Rating the quality of evidence. J Clin Epidemiol 2011;64:401-6.
77. Brunetti M, Shemilt I, Pregno S, et al. GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence. J Clin Epidemiol 2013;66:140-50.
78. Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1 Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011;64:383-94.
79. Guyatt G, Oxman AD, Sultan S, et al. GRADE guidelines: 11. Making an overall rating of confidence in effect estimates for a single outcome and for all outcomes. J Clin Epidemiol 2013;66:151-7.
80. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 2 Framing the question and deciding on important outcomes. J Clin Epidemiol 2011;64:395-400.
81. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines 6. Rating the quality of evidence-imprecision. J Clin Epidemiol 2011;64:1283-93.
82. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 8. Rating the quality of evidence-indirectness. J Clin Epidemiol 2011;64:1303-10.
83. Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol 2011;64:1294-302.
84. Guyatt GH, Oxman AD, Montori V, et al. GRADE guidelines: 5 Rating the quality of evidence-publication bias. J Clin Epidemiol 2011;64:1277-82.
85. Guyatt GH, Oxman AD, Santesso N, et al. GRADE guidelines: 12. Preparing summary of findings tables-binary outcomes. J Clin Epidemiol 2013;66:158-72.
86. Guyatt GH, Oxman AD, Sultan S, et al. GRADE guidelines: 9 Rating up the quality of evidence. J Clin Epidemiol 2011;64:1311-16.
87. Guyatt GH, Oxman AD, Vist G, et al. GRADE guidelines: 4. Rating the quality of evidence-study limitations (risk of bias). J Clin Epidemiol 2011;64:407-15.
88. Guyatt GH, Thorlund K, Oxman AD, et al. GRADE guidelines: 13. Preparing summary of findings tables and evidence profiles-continuous outcomes. J Clin Epidemiol 2013;66:173-83.
89. Andrews J, Guyatt G, Oxman AD, et al. GRADE guidelines: 15. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol 2013;66:719-25.
90. Ebrahim S, Akl EA, Mustafa RA, et al. Addressing continuous data for participants excluded from trial analysis: a guide for systematic reviewers. J Clin Epidemiol 2013;66:1014-21.e1.
91. Akl EA, Johnston BC, Alonso-Coello P, et al. Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS ONE 2013;8:e57132.
92. Ades AE, Sculpher M, Sutton A, et al. Bayesian methods for evidence synthesis in cost-effectiveness analysis. Pharmacoeconomics 2006;24:1-19.
93. Salanti G, Higgins JP, Ades AE, et al. Evaluation of networks of randomized trials. Stat Methods Med Res 2008;17:279-301.
94. Sterne JA, Davey Smith G. Sifting the evidence-what's wrong with significance tests? BMJ 2001;322:226-31.
95. Lu G, Ades A. Assessing evidence inconsistency in mixed treatment comparisons. J Stat Assoc 2006;101:447-59.
96. Salanti G, Ades AE, Ioannidis JP. Graphical methods and numerical summaries for presenting results from multiple-treatment metaanalysis: an overview and tutorial. J Clin Epidemiol 2011;64:163-71.